Nonapeptide-1

Dosing from the Literature

Published for dark spots: one randomized pilot, in which 23 adults with melasma applied a sunscreen cream combining nonapeptide-1 with phenylethyl resorcinol, aminoethyl phosphinic acid and antioxidants twice daily for 16 weeks; the paper does not give its nonapeptide-1 content (Chatterjee et al., 2021; PMID 34379946). Not published: a trial of nonapeptide-1 on its own, or any independent human trial.

Nonapeptide-1 is a topical cosmetic ingredient; "dosing" here means formulation concentration, not injected volume. The ingredient supplier sells it as a solution, listed as Water (and) Butylene Glycol (and) Dextran (and) Nonapeptide-1, and lists 1–2% of that solution in finished products; its public product page does not say how much nonapeptide-1 the solution holds. No study has given it by mouth or by injection.

What It Is

Nonapeptide-1 is a synthetic nine-amino-acid peptide (INCI name: Nonapeptide-1; CAS 158563-45-2) with the sequence Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH₂ and a molecular weight of 1,206.5 daltons (PubChem CID 10418849). It is an analog of residues 5–13 of α-melanocyte-stimulating hormone (α-MSH), the thirteen-amino-acid peptide Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂ that, with ACTH, mainly drives eumelanin production in human melanocytes (Abdel-Malek et al., 2008). Two residues in nonapeptide-1 are in the unnatural D-configuration (D-Phe at position 3 and D-Trp at position 5), which both increases enzymatic stability against skin peptidases and biases the molecule toward antagonist pharmacology rather than full agonism at MC1R (the receptor that controls skin pigment).

The peptide is sold to cosmetic makers under the trade name Melanostatine-5, a solution its supplier lists as Water (and) Butylene Glycol (and) Dextran (and) Nonapeptide-1, and to laboratories as an acetate-salt powder (Chen et al., 2022). It is not Melitane, a different peptide (acetyl hexapeptide-1) that the same supplier sells as an MC1R agonist to enhance pigmentation. Supplier datasheets list 1–2% of the solution in finished products and report melanin production in α-MSH-stimulated cells about 30% lower at 10⁻⁵ M, in mouse B16-F10 melanoma cells and cultured human melanocytes. The peptide is positioned as a "biomimetic brightener" — an ingredient that reproduces, in reverse, the natural braking mechanism that agouti-signaling protein (ASIP) exerts on MC1R during the eumelanin-to-pheomelanin switch.

The biology nonapeptide-1 targets is unusually well-characterized. Melanocytes are dendritic, neural-crest-derived pigment cells that sit at the dermoepidermal junction at a roughly 1:10 ratio to basal keratinocytes. They synthesize the pigment melanin inside specialized lysosome-related organelles called melanosomes, which mature through four distinct morphological stages (I–IV) before being transferred via dendritic processes to neighboring keratinocytes. The master transcriptional (at the gene-switching level) regulator of this program — microphthalmia-associated transcription factor (MITF) — is downstream of MC1R signaling and controls tyrosinase (TYR, the rate-limiting enzyme), tyrosinase-related protein 1 (TYRP-1, DHICA oxidase), and tyrosinase-related protein 2 (TYRP-2 / dopachrome tautomerase, DCT) expression. Nonapeptide-1's design thesis is that by competitively blocking MC1R at the top of this cascade, it reduces cAMP accumulation, suppresses MITF induction, and downregulates the enzymatic machinery of melanin biosynthesis without directly damaging the melanocyte or interfering with baseline pigmentation.

Where the compound sits in the cosmetic landscape matters. The dominant pharmaceutical lightener, hydroquinone 4%, works by competitive inhibition of tyrosinase and by cytotoxic effects on melanocytes themselves — with risks including irritant dermatitis, ochronosis, and paradoxical hyperpigmentation on chronic use. Kligman's triple combination (hydroquinone / tretinoin / fluocinolone) remains the clinical gold standard for melasma, but is not intended for long-term use. Cosmeceutical alternatives include decapeptide-12 (Lumixyl; direct tyrosinase inhibitor), arbutin, kojic acid, azelaic acid, niacinamide (inhibits melanosome transfer), tranexamic acid (reduces plasmin-driven MSH and endothelin release), cysteamine, and 4-n-butylresorcinol. Nonapeptide-1 is distinctive in attacking the signaling cascade upstream of tyrosinase rather than the enzyme itself. Whether that upstream leverage translates to measurable clinical benefit in pigmented disorders like melasma, post-inflammatory hyperpigmentation, or solar lentigines is the open question the compound has yet to answer in rigorous independent human trials.

Mechanism of Action

Nonapeptide-1 is sold as an antagonist of α-MSH (the hormone that tells skin to tan) at MC1R, the receptor through which α-MSH drives pigment. In melanocytes, α-MSH acting on MC1R raises cAMP, which through PKA and CREB increases MITF, the transcription factor behind the pigment enzymes (Chen et al., 2022); an antagonist that occupies the receptor would, in principle, damp each step. Most of the details below come from research on α-MSH and MC1R in general; the findings on nonapeptide-1 itself come from a study in human melanocytes (Chen et al., 2022).

• α-MSH antagonism at MC1R — In human melanocytes, α-MSH and ACTH act through MC1R: their binding raises cAMP and drives melanin production and cell growth (Suzuki et al., 1996). The ingredient supplier describes nonapeptide-1 as an antagonist of α-MSH, and a 2022 study used it as one in human melanocytes (Chen et al., 2022). None of the papers cited here measured its binding to MC1R or to other melanocortin receptors.
• MITF transcription-factor suppression — α-MSH's cAMP signal acts through PKA and CREB to raise MITF, the transcription factor that drives the pigment enzymes tyrosinase, tyrosinase-related protein 1 (TYRP-1) and tyrosinase-related protein 2 (TYRP-2 / DCT) (Chen et al., 2022). In human epidermal melanocytes given 20 μM nonapeptide-1 for 3 days, the levels of MITF, tyrosinase, TYRP-1, TYRP-2 and MC1R itself fell, with or without UVA (Chen et al., 2022).
• Tyrosinase-activity reduction — Decapeptide-12 inhibits the tyrosinase enzyme directly (Hantash & Jimenez, 2009). In the same human-melanocyte study, nonapeptide-1 lowered tyrosinase activity by about 13% and melanin by about 12% in unexposed cells, and brought UVA-exposed cells back to about untreated levels (Chen et al., 2022); the study did not test whether it acts on the enzyme directly.
• Eumelanin-over-pheomelanin biasing — MC1R activation drives brown-black eumelanin; agouti signaling protein (ASIP), the body's own MC1R blocker, competes with α-MSH at the receptor and is thought to shift melanocytes toward red-yellow pheomelanin (Abdel-Malek et al., 1999). In human melanocytes, ASIP blocked α-MSH's effects on cAMP, tyrosinase activity and cell growth, as agouti does in mice (Suzuki et al., 1997). The nonapeptide-1 study measured total melanin, not its type (Chen et al., 2022).
• MC1R biology beyond pigmentation — In human melanocytes, α-MSH acting on MC1R also reduces hydrogen peroxide and oxidative stress and enhances repair of UV-damaged DNA, independent of melanin (Abdel-Malek et al., 2008; Kadekaro et al., 2012). In principle, an MC1R antagonist could blunt these protective effects along with pigment; this is a theoretical concern, reviewed in the Side Effects section below.

What the Research Shows

Nonapeptide-1's published evidence base divides into two layers: (1) the adjacent biology of MC1R / α-MSH / MITF / tyrosinase, which is deep, independent, and robust; and (2) nonapeptide-1-specific data, which is shallow, supplier-led, and composed mainly of cell-culture and small in-vivo cosmetic panels. Both layers deserve separate weighting.

• α-MSH / MC1R biology is strongly established — Normal human melanocytes respond to α-MSH and ACTH with increased cAMP, tyrosinase activity, melanogenesis, and proliferation (Suzuki, Endocrinology 1996; PMID 8612494). α-MSH binds MC1R with nanomolar affinity; ACTH is equipotent; β-MSH is slightly less potent; γ-MSH is effectively inactive at MC1R (Schiöth, Eur J Pharmacol 1995; PMID 7774675). MC1R loss-of-function variants (Arg151Cys, Arg160Trp, Asp294His) reduce or abolish α-MSH responsiveness, map to red-hair/fair-skin phenotype, and increase melanoma risk (Abdel-Malek, Pigment Cell Res 2000; PMID 11041375).
• MC1R is the canonical brightening target — Abdel-Malek and colleagues' program at Cincinnati has repeatedly demonstrated that MC1R activation by α-MSH analogs (NDP-MSH / melanotan-I, tetrapeptide analogs, tripeptide analogs) robustly stimulates eumelanogenesis and supports UV-damage repair (Abdel-Malek, FASEB J 2006 [melanoma prevention tetrapeptide analogs; PMID 16723376]; Abdel-Malek, Photochem Photobiol 2008 tripeptide analog review; PMID 18282187). A competitive antagonist at the same receptor logically produces the opposite effect — less eumelanin, lighter skin — which is the foundation of nonapeptide-1's mechanistic claim.
• Endogenous MC1R antagonists provide biological proof-of-concept — Agouti-signaling protein (ASIP) is a natural inverse agonist of MC1R that switches mouse hair banding to yellow and, in humans, is associated with red hair and fair skin when overexpressed. Human β-defensin 3 (HBD3) is a natural MC1R blocker that prevents both α-MSH and ASIP binding. These endogenous antagonists establish that physiological MC1R antagonism can and does brighten mammalian pigmentation — nonapeptide-1 is a pharmacological imitation of this natural regulatory axis (Herraiz, Pigment Cell Melanoma Res 2021; PMID 33884776).
• Tyrosinase / TYRP-1 / TYRP-2 form the enzymatic endpoint — The three-enzyme melanogenic cassette downstream of MITF is well-characterized: tyrosinase (the rate-limiting dopa-oxidase), TYRP-1 (DHICA oxidase; Kobayashi, EMBO J 1994; PMID 7813420), and TYRP-2 / DCT (dopachrome tautomerase; Tsukamoto, EMBO J 1992; PMID 1537333). Any upstream signaling inhibitor that reduces MITF — as nonapeptide-1 is claimed to do — will reduce the abundance and activity of all three enzymes over days to weeks (Yamaguchi and Hearing, Cold Spring Harb Perspect Med 2014; PMID 24789876).
• Nonapeptide-1 in-vitro datasheet claims — Manufacturer mechanistic studies (IFF / Lucas Meyer Cosmetics technical documentation; reproduced in commercial ingredient and peptide-supplier databases) report Ki ≈ 40 nM at MC1R, IC₅₀ ≈ 2.5 nM for α-MSH-induced cAMP in cultured human melanocytes, IC₅₀ ≈ 11 nM for α-MSH-induced melanosome dispersion, and ~33% reduction in α-MSH-stimulated melanin production at 10⁻⁵ M. These are the headline numbers repeated across cosmetic-ingredient listings but are not validated against an independent peer-reviewed trial in PubMed-indexed literature.
• Cosmetic efficacy panels — The ingredient supplier's product page claims "lightening activity proven on Asian skin"; the testing behind the claim is not published. The one published human study is an industry-funded randomized pilot in which 23 adults with melasma used a sunscreen cream containing nonapeptide-1 and other actives for 16 weeks and 23 used the sunscreen alone; the differences in melasma severity and Mexameter melanin readings were not statistically significant (Chatterjee et al., 2021; PMID 34379946).
• Comparative context: broader topical-brightening evidence — Systematic reviews of topical melasma and hyperpigmentation treatments (Austin, J Drugs Dermatol 2019 [PMID 31741361]; Searle, Dermatol Ther 2020 [PMID 32720446]) consistently conclude that hydroquinone (particularly in triple combination), tranexamic acid, cysteamine, and niacinamide have the strongest randomized-controlled-trial support. Peptide brighteners (decapeptide-12 / Lumixyl, nonapeptide-1, oligopeptide-34, etc.) are acknowledged as mechanistically interesting but rated as evidence-limited. Recent reviews of novel peptide designs for anti-melanogenesis (Putri et al., Drug Des Devel Ther 2025 [PMID 39896936]) emphasize the same point: the design space is promising, the confirmatory human data are sparse.
• No nonapeptide-1-specific randomized controlled trial in PubMed — As of October 2026, PubMed indexes no randomized controlled trial of nonapeptide-1 on its own, and ClinicalTrials.gov lists no trial of it. The one blinded, randomized trial in a pigmentary disorder tested a sunscreen cream that combines it with other actives (Chatterjee et al., 2021; PMID 34379946). This is the central honest limitation of the compound.

Human Data

Human data specifically on nonapeptide-1 are largely confined to manufacturer-sponsored in-vivo cosmetic efficacy panels and in-vitro human-melanocyte culture studies. Independent peer-reviewed clinical trials are not presently available. The following summarizes the character of the available human-related evidence.

• Cultured human epidermal melanocytes — In a published study in human epidermal melanocytes, 20 μM nonapeptide-1 for 3 days lowered melanin by about 12% and tyrosinase activity by about 13% in cells not exposed to UVA, and lowered MITF and the pigment enzymes with or without UVA (Chen et al., 2022). These are in-vitro readouts, not clinical outcomes.
• Supplier in-vivo panels — The ingredient supplier's product page claims "lightening activity proven on Asian skin". The panel behind the claim is not published, so its size, design and results cannot be checked.
• No randomized trial of nonapeptide-1 on its own — A PubMed search for "nonapeptide-1" (October 2026) finds one randomized trial that included it: an industry-funded pilot of a sunscreen cream combining it with other actives, in 46 adults with melasma, with no statistically significant difference from sunscreen alone (Chatterjee et al., 2021). The closest adjacent peer-reviewed peptide-brightening human data is for decapeptide-12 (Lumixyl; direct tyrosinase inhibitor), which does have peer-reviewed clinical efficacy reports in melasma (Hantash and Jimenez 2009, 2012).
• No ClinicalTrials.gov registration — A search of ClinicalTrials.gov for "nonapeptide-1" or "Melanostatine" returns no active or completed trials. The compound has not entered the investigational-drug pipeline.
• Post-market cosmetic safety profile — Nonapeptide-1 has been in commercial cosmetic use since the mid-2000s and appears in hundreds of marketed formulations. No significant post-market adverse-event signal has been reported in pharmacovigilance or cosmetic-safety databases. Irritation, contact dermatitis, and sensitization are reported at the background rates expected for cosmetic peptide ingredients.
• Regulatory position — Listed on the U.S. FDA Voluntary Cosmetic Registration Program database as an INCI-recognized cosmetic ingredient. Listed in the European Commission CosIng ingredient database. No pharmaceutical registration in any jurisdiction.

Nonapeptide-1 is a cosmetic ingredient, not a clinically tested depigmenting agent: no trial has tested it on its own. In a systematic review of randomized trials of topical melasma treatments, cysteamine, triple-combination cream and tranexamic acid received strong recommendations (Austin et al., 2019).

Reconstitution & Storage

Nonapeptide-1 is a topical cosmetic ingredient, not an injectable peptide: nothing is reconstituted with bacteriostatic water. Cosmetic makers buy it as a solution, which its supplier lists as Water (and) Butylene Glycol (and) Dextran (and) Nonapeptide-1; laboratories buy the acetate-salt powder, the form a 2022 cell study used (Chen et al., 2022). The supplier's public product page gives no storage temperature or shelf life, and no study has given nonapeptide-1 by injection.

→ Calculator — vial-to-syringe math

Side Effects & Risks

No published study reports the safety of nonapeptide-1 on its own; most lines below are theoretical, drawn from MC1R biology.

• Topical tolerability — No study has measured skin reactions to nonapeptide-1 on its own. In the randomized pilot of a sunscreen cream containing it, 1 of 17 people using the cream reported itching over 16 weeks, against 4 of 15 using the sunscreen alone (itching, burning, redness or allergic contact dermatitis) (Chatterjee et al., 2021; PMID 34379946).
• UV-photoprotection consideration — In human melanocytes, MC1R activation by α-MSH contributes to photoprotection: it drives eumelanin, lowers oxidative stress through p53 and enhances repair of UV-induced DNA damage (Kadekaro et al., 2012; PMID 22622028). In principle, a topical MC1R antagonist could blunt this protection along with pigment; no published study has tested whether nonapeptide-1 does so in skin.
• Oxidative-damage considerations — In human melanocytes, melanocortins such as α-MSH reduce hydrogen peroxide generation (Abdel-Malek et al., 2008; PMID 18282187); blocking MC1R could, in theory, remove that effect.
• Pregnancy and lactation — No published study has looked at nonapeptide-1 in pregnancy or breastfeeding.
• Pediatric use — Not studied in children.
• No WADA implications — As a topical cosmetic peptide, nonapeptide-1 is not on the WADA prohibited list and has no athletic-performance implications. It is not a hypothalamic-pituitary axis modulator and has no systemic hormone-mimetic activity at cosmetic concentrations.
• No known drug interactions — None reported; no interaction study of nonapeptide-1 has been published.

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for nonapeptide-1. The one randomized pilot of a cream containing it graded melasma severity, scored MASI and took Mexameter melanin readings every 4 weeks, and recorded side effects (Chatterjee et al., 2021; PMID 34379946).

Commonly Stacked With

Ingredient lists of marketed creams and serums show nonapeptide-1 combined with other brightening ingredients. Only one combination containing it has been tested in people, in a sunscreen cream (Chatterjee et al., 2021).

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

Pigmentation-targeting cosmetic peptides and α-MSH-axis compounds:

Next Steps

References

1. Abdel-Malek Z, Scott MC, Suzuki I, Tada A, Im S, Lamoreux L, Ito S, Barsh G, Hearing VJ. The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation. Pigment Cell Res. 2000;13 Suppl 8:156-162. PMID: 11041375. (Foundational human MC1R loss-of-function / gain-of-function pigmentation biology.)
2. Suzuki I, Cone RD, Im S, Nordlund J, Abdel-Malek ZA. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology. 1996;137(5):1627-1633. PMID: 8612494. (Original characterization of α-MSH / ACTH binding and function at human MC1R.)
3. Abdel-Malek Z, Suzuki I, Tada A, Im S, Akcali C. The melanocortin-1 receptor and human pigmentation. Ann N Y Acad Sci. 1999;885:117-133. PMID: 10816645. (Review of MC1R biology in human cutaneous pigmentation.)
4. Hunt G, Kyne S, Wakamatsu K, Ito S, Thody AJ. Nle4DPhe7 alpha-melanocyte-stimulating hormone increases the eumelanin:phaeomelanin ratio in cultured human melanocytes. J Invest Dermatol. 1995;104(1):83-85. PMID: 7798647. (NDP-MSH / melanotan-I demonstration of agonist-driven eumelanin shift — the pharmacological inverse of nonapeptide-1.)
5. Schiöth HB, Muceniece R, Wikberg JE, Chhajlani V. Characterisation of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol. 1995;288(3):311-317. PMID: 7774675. (MC1 / MC3 / MC4 / MC5 ligand selectivity — the subtype pharmacology relevant to MC1R selectivity claims.)
6. Abdel-Malek ZA, Kadekaro AL, Kavanagh RJ, Todorovic A, Koikov LN, McNulty JC, Jackson PJ, Millhauser GL, Schwemberger S, Babcock G, Haskell-Luevano C, Knittel JJ. Melanoma prevention strategy based on using tetrapeptide α-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J. 2006;20(9):1561-1563. PMID: 16723376. (α-MSH tetrapeptide agonist analogs for UV-protective eumelanogenesis — demonstrates that MC1R modulation in either direction is bioactive.)
7. Abdel-Malek ZA, Knittel J, Kadekaro AL, Swope VB, Starner R. The melanocortin 1 receptor and the UV response of human melanocytes — a shift in paradigm. Photochem Photobiol. 2008;84(2):501-508. PMID: 18282187. (Review of MC1R signaling cascade including cAMP, MITF, and UV-induced DNA damage repair.)
8. Kadekaro AL, Chen J, Yang J, Chen S, Jameson J, Swope VB, Cheng T, Kadakia M, Abdel-Malek Z. Alpha-melanocyte-stimulating hormone suppresses oxidative stress through a p53-mediated signaling pathway in human melanocytes. Mol Cancer Res. 2012;10(6):778-786. PMID: 22622028. (Documents the UV-protective / oxidative-stress arm of α-MSH signaling — relevant context for MC1R-antagonist risk framing.)
9. Herraiz C, Martínez-Vicente I, Maresca V. The α-melanocyte-stimulating hormone/melanocortin-1 receptor interaction: A driver of pleiotropic effects beyond pigmentation. Pigment Cell Melanoma Res. 2021;34(4):748-761. PMID: 33884776. (Current comprehensive review of α-MSH/MC1R signaling including cAMP/PKA, ERK1/2, PI3K/AKT, and non-pigmentary pleiotropic effects.)
10. Yamaguchi Y, Hearing VJ. Melanocytes and their diseases. Cold Spring Harb Perspect Med. 2014;4(5):a017046. PMID: 24789876. (Authoritative review of melanocyte biology, melanosome maturation, MITF, and the tyrosinase / TYRP-1 / TYRP-2 enzymatic cascade — the downstream endpoint of nonapeptide-1 antagonism.)
11. Tsukamoto K, Jackson IJ, Urabe K, Montague PM, Hearing VJ. A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J. 1992;11(2):519-526. PMID: 1537333. (Original characterization of TRP-2 / DCT as the dopachrome tautomerase — part of the downstream melanogenic machinery suppressed indirectly by MC1R antagonism.)
12. Kobayashi T, Urabe K, Winder A, Jiménez-Cervantes C, Imokawa G, Brewington T, Solano F, García-Borrón JC, Hearing VJ. Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. EMBO J. 1994;13(24):5818-5825. PMID: 7813420. (Functional characterization of TRP-1 as DHICA oxidase — the TRP-1 component of the tyrosinase enzyme family.)
13. Kameyama K, Sakai C, Kuge S, Nishiyama S, Tomita Y, Ito S, Wakamatsu K, Hearing VJ. The expression of tyrosinase, tyrosinase-related proteins 1 and 2 (TRP1 and TRP2), the silver protein, and a melanogenic inhibitor in human melanoma cells of differing melanogenic activities. Pigment Cell Res. 1995;8(2):97-104. PMID: 7659683. (Documentation of tyrosinase / TRP-1 / TRP-2 expression in human melanoma / melanocyte cell lines — the reference framework for MITF downstream effects.)
14. Swope VB, Abdel-Malek ZA. MC1R: Front and Center in the Bright Side of Dark Eumelanin and DNA Repair. Int J Mol Sci. 2018;19(9):2667. PMID: 30205559. (Review positioning MC1R as a master regulator of pigmentation and UV-damage response.)
15. Suzuki I, Tada A, Ollmann MM, Barsh GS, Im S, Lamoreux ML, Hearing VJ, Nordlund JJ, Abdel-Malek ZA. Agouti signaling protein inhibits melanogenesis and the response of human melanocytes to alpha-melanotropin. J Invest Dermatol. 1997;108(6):838-842. PMID: 9182807. (Endogenous MC1R antagonism by ASIP — the natural biological precedent for nonapeptide-1's pharmacology.)
16. Austin E, Nguyen JK, Jagdeo J. Topical treatments for melasma: A systematic review of randomized controlled trials. J Drugs Dermatol. 2019;18(11):1156-1163. PMID: 31741361. (Systematic review of RCT evidence for topical melasma treatments — the evidence-quality benchmark that nonapeptide-1 does not yet meet.)
17. Searle T, Al-Niaimi F, Ali FR. The top 10 cosmeceuticals for facial hyperpigmentation. Dermatol Ther. 2020;33(6):e14095. PMID: 32720446. (Cosmeceutical landscape review — the context in which peptide brighteners sit.)
18. Putri SA, Maharani R, Maksum IP, Siahaan TJ. Peptide design for enhanced anti-melanogenesis: Optimizing molecular weight, polarity, and cyclization. Drug Des Devel Ther. 2025;19:645-670. PMID: 39896936. (Recent review of anti-melanogenic peptide design principles — frames where nonapeptide-1's nine-residue D-amino-acid scaffold sits in the peptide-brightener design space.)
19. Hantash BM, Jimenez F. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol. 2009;8(8):732-735. PMID: 19663110. (Decapeptide-12 melasma pilot — the closest published peptide-brightening human comparator to nonapeptide-1.)
20. Hantash BM, Jimenez F. Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system. J Drugs Dermatol. 2012;11(5):660-662. PMID: 22527440. (Follow-up decapeptide-12 melasma open-label trial — the peptide brightener with the most published independent human data.)
21. Schiöth HB, Muceniece R, Larsson M, Mutulis F, Szardenings M, Prusis P, Lindeberg G, Wikberg JES. Selectivity of cyclic [D-Phe7] and [D-Nal7] substituted MSH analogues for the melanocortin receptor subtypes. Peptides. 1997;18(7):1009-1013. PMID: 9357059. (D-amino-acid substitution strategy in MSH analogs — methodological precedent for the D-Phe / D-Trp residues in nonapeptide-1.)
22. Chen J, Li H, Liang B, Zhu H. Effects of tea polyphenols on UVA-induced melanogenesis via inhibition of α-MSH-MC1R signalling pathway. Postepy Dermatol Alergol. 2022;39(2):327-335. PMID: 35645678. (Independent mechanistic confirmation that α-MSH-MC1R antagonism reduces UVA-induced melanogenesis — supports the mechanistic thesis underlying nonapeptide-1.)
23. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
24. Chatterjee M, Neema S, Rajput GR. A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance. Indian J Dermatol Venereol Leprol. 2021;88(1):51-58. PMID: 34379946. doi:10.25259/IJDVL_976_18. (Double-blind randomized pilot in 46 adults with melasma: a sunscreen cream combining nonapeptide-1 with phenylethyl resorcinol, aminoethyl phosphinic acid and antioxidants, against sunscreen alone, for 16 weeks after triple combination; differences not statistically significant; industry-funded.)

Related Research

• AHK-CuCopper Tripeptide (Hair)
• ArgirelineSNAP-25 Mimetic
• Decapeptide-12Tyrosinase Inhibitor
• MatrixylCollagen Signal Peptide
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.